WO2024246285 - SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
National phase entry is expected:
Publication Number
WO/2024/246285
Publication Date
05.12.2024
International Application No.
PCT/EP2024/065036
International Filing Date
31.05.2024
Title **
[English]
SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
[French]
AGONISTES DU RÉCEPTEUR DE L'OREXINE 2 SPIROMACROCYCLIQUES
Applicants **
H. LUNDBECK A/S
Inventors
JUHL, Karsten
ASCIC, Erhad
YU, Wanwan
ANDERSEN, Thomas, Leegaard
MIKKELSEN, Gitte, Kobberøe
HANSEN, Anders, Højgaard
LINDOVSKÁ, Petra
PLANAS PADRÓS, Ferran
ARNOLD, Andreas, Michael
KERÄNEN, Henrik, Juhani
BÆK, Michael
Priority Data
23176747.6
01.06.2023
EP
24174838.3
08.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4172 | |
| EPO | Filing, Examination, Granting | 17677 | |
| Japan | Filing, Examination, Granting | 2293 | |
| South Korea | Filing, Examination, Granting | 2216 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
32,898
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.[French]
La présente invention concerne de nouveaux composés spiro-macrocycliques de formule générale (I) qui sont des agonistes du récepteur de l'orexine 2.